TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01644968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 anti-OX40
Description: 0.1 mg/kg anti-OX40 on days 1, 3, and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 anti-OX40
Description: 0.1 mg/kg anti-OX40 on days 1, 3, and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 anti-OX40
Description: .4 mg/kg anti-OX40 on days 1, 3, and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 anti-OX40
Description: .4 mg/kg anti-OX40 on days 1, 3, and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 anti-OX40
Description: 2.0 mg/kg anti-OX40 on days 1, 3, and 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 3 anti-OX40
Description: 2.0 mg/kg anti-OX40 on days 1, 3, and 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Day 29
Description: Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Day 1
Description: Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH Day 1
Description: 1 mg KLH in 1 cc diluent subcutaneously on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH Day 29
Description: 1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
Study: NCT03661346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Aliquots of 20mg of Labetol~• Maximum Dose - 300mg total for case

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Infusion - 0.1mg/kg/min~• Maximum Dose - after 30 minutes, 0.3mg/kg/min
Study: NCT00361790

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
Description: Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
Study: NCT04490772

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory tests
Description: Laboratory tests such as CBC, Liver function and CRP
Study: NCT04269317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel C
Description: Thermo-mechanical technology for fractional treatment of human skin. Dermal heating and coagulative effect that occur during the treatment session provide for dermal remodeling and collagen restructuring that promote acne scar appearance improvement.
Study: NCT00457951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-Label
Description: ODSH administered open-label

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
Description: Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ODSH
Description: Randomized, Blinded, ODSH Arm
Study: NCT01041027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo HDR brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01004822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVX-241
Description: 25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
Study: NCT02410057

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-reduced α-lactalbumin formula
Description: Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein-reduced whey formula
Description: Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Standard infant formula
Study: NCT03878108

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LCHF diet
Description: low-carbohydrate, high-fat (LCHF)diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LCHF diet
Description: low-carbohydrate, high-fat (LCHF)diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LFHC diet
Description: low-fat, high-carbohydrate (LFHC) diet

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LFHC diet
Description: low-fat, high-carbohydrate (LFHC) diet
Study: NCT00354991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium (+) hydrochlorothiazide
Description: Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
Study: NCT03126175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below elbow immobilization
Description: 20cm wide gypsum in the forearm cut to fit the thumb.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Above elbow immobilization
Description: 20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
Study: NCT02071823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
Study: NCT02400697

Intervention type: OTHER
Intervention: <30 wks gestation or 1500 grams
Description: Outcomes of preterm infants recorded

Intervention type: OTHER
Intervention: <30 wks gestation or 1500 grams
Description: Outcomes of preterm infants recorded
Study: NCT00509275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0027
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0027
Description: capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: W0027
Description: capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03297593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: 240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: After 2 weeks 1mg/kg every 6 weeks
Study: NCT03202329

Intervention type: OTHER
Group type: OTHER
Intervention: standard care
Description: cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon

Intervention type: OTHER
Group type: OTHER
Intervention: Nurse-based care
Description: board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
Study: NCT03115723

Intervention type: PROCEDURE
Intervention: Percutaneous coronary intervention

Intervention type: PROCEDURE
Intervention: Coronary angiography
Study: NCT02909127

Intervention type: OTHER
Intervention: SWALLOWING EVALUATION
Description: Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

Intervention type: OTHER
Intervention: The Functional Independence Measure
Description: The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.

Intervention type: OTHER
Intervention: The PEDI-EAT-10
Description: The PEDI-EAT-10 will also be administered.

Intervention type: OTHER
Intervention: The PEDI-EAT-10
Description: The PEDI-EAT-10 will also be administered.
Study: NCT01692990

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil
Description: For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
Study: NCT02513732

Intervention type: DEVICE
Intervention: XIENCE Xpedition 2.25 mm stent
Description: Patients receiving XIENCE Xpedition 2.25 mm stent
Study: NCT00860756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation CD
Description: A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
Study: NCT00993941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous BMSCs transplantation
Description: 10 ml autologous BMSCs(7\~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conserved therapy
Description: Oral or intravenous administration
Study: NCT01477541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PM/ON integration
Description: Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
Study: NCT02390869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R2-MANT
Description: A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-MANT
Description: A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
Study: NCT04672434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized anti-PD-1 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized anti-PD-1 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized anti-PD-1 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized anti-PD-1 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized anti-PD-1 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym021
Description: Sym021 is a humanized anti-PD-1 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.
Study: NCT04801992

Intervention type: DEVICE
Intervention: MINI WELL Ready (SIFI SpA, Italy)
Description: Implantation during cataract surgery of the progressive extended depth of focus intraocular lens for the posterior chamber to replace the crystalline lens in the correction of aphakia in adult patients.
Study: NCT04672434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym024
Description: Sym024 is an anti-CD73 antibody.
Study: NCT03640078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acquisition imaging
Description: The usual care of the sera will not be modified, only a phase of acquisition of the images will be added to the analysis
Study: NCT02776917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirmtuzumab + Paclitaxel
Description: Cirmtuzumab and paclitaxel may be administered until disease progression or unacceptable toxicity. Cirmtuzumab or paclitaxel may be continued alone if the other drug is discontinued due to toxicity.
Study: NCT04553185

Intervention type: OTHER
Intervention: Study procedure
Description: All participants will undergo a collection of demographic data, personal and family history for PD, a neurological examination and administration of clinical scales. All participants will undergo a collection of venous blood sample. At the end of the visit they will receive a wristwatch to monitor their sleep at home (Actigraph) and a sleep diary, together with a prepaid envelope to post the watch and the diary back to the investigators. They will also receive a link for a series of online tests for non-motor symptoms related to Parkinson's disease that they can complete remotely at home.
Study: NCT02960022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Subjects will receive enzalutamide orally once daily at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzalutamide
Description: Subjects will receive enzalutamide orally once daily at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
Study: NCT03960788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoxetate Sodium
Description: Gadoxetate Sodium is an FDA approved contrast agent to be used during magnetic resonance imaging.
Study: NCT02528331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Study: NCT00942188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189102
Description: Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189102
Description: Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189102
Description: Participants received 2 subcutaneous (SC) injections weekly for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received 2 SC injections weekly for 12 weeks.
Study: NCT02528331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Study: NCT02058940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: 50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
Study: NCT02515890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Selected subjects received this drug during a portion of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Selected subjects received this drug during a portion of the study
Study: NCT03603275

Intervention type: DRUG
Intervention: New FVIII products
Description: Kovaltry or Jivi prescribed by the treating Physician
Study: NCT00857909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiloride
Description: 1 tablet twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 1 tablet twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04198194

Intervention type: DIAGNOSTIC_TEST
Intervention: Predictors of events
Description: Apple Heart \& Movement Study in Apple Research app
Study: NCT03474666

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strict Glycemic Control Group
Description: The strict protocol adopted to conduct the study was proposed by Keegan e Cols.(2010) to be used among adult LT recipients that consist of a continuous intravenous insulin infusion. The targeted blood glucose range is 80-130 mg/dL. The procedure must be stopped when the patient can ingest at least 50% of liquid diet or receive bolus tube feedings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Glycemic Control Group
Description: The targeted blood glucose range is 130-180 mg/dL~* Blood glucose reading: ≤ 180 mg/dL - subcutaneous insulin dose: 0~* Blood glucose reading: ≥181 mg/dL and ≤250 mg/dL - subcutaneous insulin dose: 5 IU~* Blood glucose reading: ≥251 mg/dL and ≤300 mg/dL - subcutaneous insulin dose: 10 IU~* Blood glucose reading: ≥301 - subcutaneous insulin dose: 15 IU
Study: NCT00857909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and spironolactone
Description: 5mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: 25mg twice daily
Study: NCT02515890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Selected subjects received this drug during a portion of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Selected subjects received this drug during a portion of the study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation
Description: Experimental acute pain stimulus was delivered using a nerve stimulator. These painful shocks were paired randomly with some of the auditory experimental cues.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Selected subjects received this drug during a portion of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Selected subjects received this drug during a portion of the study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Selected subjects received this drug during a portion of the study
Study: NCT04519827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Rice-based hydrolysate
Description: A rice-based hydrolysed infant formula with new ingredient
Study: NCT02395406

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation with Totaltrack

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheal intubation with Airtraq
Study: NCT04519827

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Amino Acid-based infant formula
Description: An amino acid-based infant formula